NCT06909500 A Digital Intervention (ACT on Vaping App) for Vaping Cessation in Young Adult E-Cigarette Users
| NCT ID | NCT06909500 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fred Hutchinson Cancer Center |
| Condition | Nicotine Dependence |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,178 participants |
| Start Date | 2026-06-15 |
| Primary Completion | 2027-11-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,178 participants in total. It began in 2026-06-15 with a primary completion date of 2027-11-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial evaluates a smartphone application (app) called Acceptance and Commitment Therapy (ACT) on Vaping for helping young adults quit using electronic cigarettes (e-cigarettes). E-cigarettes pose numerous risks, particularly to youth and young adults. Addressing the high prevalence of e-cigarette use by young adults requires effective and accessible treatments to support current users to quit. Research shows this group prefers and benefits from newer methods of treatment delivery such as digital interventions. ACT on Vaping is a digital therapeutic intended to deliver behavioral therapy to young adults who vape to motivate and support abstinence from all nicotine and tobacco products. The app contains sessions that promote awareness of cues that trigger tobacco use and teach skills for responding to these triggers in a way that is tailored for the participant's readiness to quit. Receiving access to the ACT on Vaping app may be effective in helping young adults quit vaping.
Eligibility Criteria
Inclusion Criteria: * Age 18-30 * Current weekly user of e-cigarette product(s) for the last 30 days * Has a smartphone; either an Android (running version 12 or higher) or iPhone (running iOS version 17 or higher, iPhone 11 or more recent) * Experience downloading and using one or more apps on their smartphone * Have a mobile data plan and/or access to WiFi to support the use of the ACT on Vaping app * Has access to text messaging * Has an email address * United States (US) resident, with a US mailing address * Willing to complete all study procedures * Comfortable reading and writing in English Exclusion Criteria: * Currently using other tobacco cessation treatments at the time of screening, including pharmacotherapy or behavioral support (note: use of these treatment is allowable during trial participation) * Member of the same household as another research participant * Currently in prison * Google voice number as sole phone number, due to its association with fraudulent study entry attempts * Is ineligible per fraud prevention protocol * Employees/family of investigator or study center
Contact & Investigator
Jaimee Heffner, PhD
PRINCIPAL INVESTIGATOR
Fred Hutch/University of Washington Cancer Consortium
Frequently Asked Questions
Who can join the NCT06909500 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 30 Years, studying Nicotine Dependence. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06909500 currently recruiting?
Yes, NCT06909500 is actively recruiting participants. Contact the research team at jheffner@fredhutch.org for enrollment information.
Where is the NCT06909500 trial being conducted?
This trial is being conducted at Seattle, United States.
Who is sponsoring the NCT06909500 clinical trial?
NCT06909500 is sponsored by Fred Hutchinson Cancer Center. The principal investigator is Jaimee Heffner, PhD at Fred Hutch/University of Washington Cancer Consortium. The trial plans to enroll 1,178 participants.